Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.
- Zacks•5 days ago
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
- Investopedia•6 days ago
Shire is planning a late-stage study for its SHP655 drug to treat a rare enzyme deficiency.
SHPG : Summary for Shire plc - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||176.81 x 200|
|Ask||179.51 x 500|
|Day's Range||176.63 - 178.08|
|52 Week Range||161.09 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||142.83|
|Dividend & Yield||0.91 (0.52%)|
|1y Target Est||N/A|